2019 Videos Archives

AMP 2019 Video Series Part 4 of 4

2025-06-11T10:56:55-07:00November 6th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

AMP 2019 Video Series Part 3 of 4

2025-06-11T10:55:30-07:00November 6th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

AMP 2019 Video Series Part 2 of 4

2025-06-11T10:58:02-07:00November 6th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

AMP 2019 Video Series Part 1 of 4

2025-06-11T11:10:06-07:00November 6th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

Invivoscribe – EHA 2019: Part 3 of 3

2025-06-11T11:10:53-07:00June 13th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

Invivoscribe – EHA 2019: Part 2 of 3

2025-06-11T11:11:55-07:00June 13th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

Invivoscribe – EHA 2019: Part 1 of 3

2025-06-11T11:13:02-07:00June 13th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

Invivoscribe – ASCO – LeukoStrat CDx FLT3 Mutation Assay

2025-06-11T11:14:50-07:00June 1st, 2019|2019 Videos, Featured Videos, Videos|

Watch video

AMP Global 2019 Video Series Part 4 of 4

2025-06-11T11:15:24-07:00May 16th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

AMP Global 2019 Video Series Part 3 of 4

2025-06-11T11:16:05-07:00May 16th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

AMP Global 2019 Video Series Part 2 of 4

2025-06-11T11:16:49-07:00May 16th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

AMP Global 2019 Video Series Part 1 of 4

2025-06-02T14:12:09-07:00May 16th, 2019|2019 Videos, Featured Videos, Videos|

Watch video

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

AMP 2019 Video Series Part 4 of 4

AMP 2019 Video Series Part 3 of 4

AMP 2019 Video Series Part 2 of 4

AMP 2019 Video Series Part 1 of 4

Invivoscribe – EHA 2019: Part 3 of 3

Invivoscribe – EHA 2019: Part 2 of 3

Invivoscribe – EHA 2019: Part 1 of 3

Invivoscribe – ASCO – LeukoStrat CDx FLT3 Mutation Assay

AMP Global 2019 Video Series Part 4 of 4

AMP Global 2019 Video Series Part 3 of 4

AMP Global 2019 Video Series Part 2 of 4

AMP Global 2019 Video Series Part 1 of 4

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia

Assessment of Bone Marrow Involvement in B-Cell non-Hodgkin Lymphoma Using Immunoglobulin Gene Rearrangement Analysis with Next-Generation Sequencing

Evaluation of Next-Generation Sequencing Versus Next-Generation Flow Cytometry for Minimal Residual Disease Detection in Chinese Patients with Multiple Myeloma

Lymphoma

Browse our comprehensive menu of product & testing services.

Myeloma

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.